Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on liver and cardiometabolic diseases, has announced its participation in two upcoming investor conferences. Management will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, with a fireside chat at 10:00 AM ET, and the Jefferies Global Healthcare Conference on June 4, 2025, with a fireside chat at 9:55 AM ET. Both events will take place in New York, and webcasts will be available on Altimmune's website. The company will also be available for one-on-one meetings during these conferences.
Altimmune (Nasdaq: ALT), un'azienda biofarmaceutica in fase clinica avanzata focalizzata su malattie epatiche e cardiometaboliche, ha annunciato la sua partecipazione a due prossime conferenze per investitori. La direzione parteciperà alla 3ª Conferenza Annuale BioConnect per Investitori di H.C. Wainwright il 20 maggio 2025, con un incontro informale alle 10:00 ET, e alla Conferenza Globale sulla Sanità di Jefferies il 4 giugno 2025, con un incontro informale alle 9:55 ET. Entrambi gli eventi si terranno a New York e saranno disponibili webcast sul sito web di Altimmune. L'azienda sarà inoltre disponibile per incontri individuali durante queste conferenze.
Altimmune (Nasdaq: ALT), una compañía biofarmacéutica en etapa clínica avanzada centrada en enfermedades hepáticas y cardiometabólicas, ha anunciado su participación en dos próximas conferencias para inversores. La dirección asistirá a la 3ª Conferencia Anual BioConnect para Inversores de H.C. Wainwright el 20 de mayo de 2025, con una charla informal a las 10:00 AM ET, y a la Conferencia Global de Salud de Jefferies el 4 de junio de 2025, con una charla informal a las 9:55 AM ET. Ambos eventos se llevarán a cabo en Nueva York y habrá transmisiones en vivo disponibles en el sitio web de Altimmune. La compañía también estará disponible para reuniones individuales durante estas conferencias.
Altimmune (Nasdaq: ALT)는 간 및 심장대사 질환에 중점을 둔 후기 임상 단계의 바이오제약 회사로, 두 개의 예정된 투자자 회의에 참여할 것이라고 발표했습니다. 경영진은 2025년 5월 20일 H.C. Wainwright 제3회 연례 BioConnect 투자자 회의에서 오전 10시(동부 시간)에 파이어사이드 채팅에 참석하며, 2025년 6월 4일 Jefferies 글로벌 헬스케어 컨퍼런스에서 오전 9시 55분(동부 시간)에 파이어사이드 채팅을 진행할 예정입니다. 두 행사는 모두 뉴욕에서 개최되며, Altimmune 웹사이트에서 웹캐스트를 시청할 수 있습니다. 또한 회사는 이 회의 기간 동안 1:1 미팅도 제공합니다.
Altimmune (Nasdaq : ALT), une société biopharmaceutique en phase clinique avancée spécialisée dans les maladies hépatiques et cardiométaboliques, a annoncé sa participation à deux prochaines conférences pour investisseurs. La direction assistera à la 3e conférence annuelle BioConnect pour investisseurs de H.C. Wainwright le 20 mai 2025, avec une discussion informelle à 10h00 ET, ainsi qu'à la conférence mondiale sur la santé de Jefferies le 4 juin 2025, avec une discussion informelle à 9h55 ET. Les deux événements auront lieu à New York et des webdiffusions seront disponibles sur le site web d'Altimmune. La société sera également disponible pour des réunions individuelles durant ces conférences.
Altimmune (Nasdaq: ALT), ein biopharmazeutisches Unternehmen in der späten klinischen Phase mit Fokus auf Leber- und kardiometabolische Erkrankungen, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Management wird am 3. jährlichen H.C. Wainwright BioConnect Investorenkonferenz am 20. Mai 2025 mit einem Fireside-Chat um 10:00 Uhr ET teilnehmen und an der Jefferies Global Healthcare Conference am 4. Juni 2025 mit einem Fireside-Chat um 9:55 Uhr ET. Beide Veranstaltungen finden in New York statt, und Webcasts werden auf der Website von Altimmune verfügbar sein. Das Unternehmen steht während dieser Konferenzen auch für Einzelgespräche zur Verfügung.
- None.
- None.
GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
- H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, NY)
Tuesday, May 20, 2025
Fireside Chat at 10:00 a.m. Eastern Time
- Jefferies Global Healthcare Conference (New York, NY)
Wednesday, June 4, 2025
Fireside Chat at 9:55 a.m. Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Phone: 619-849-5383
Jake.robison@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Altimmune (ALT) presenting at the H.C. Wainwright BioConnect Conference 2025?
What time is Altimmune's presentation at the Jefferies Global Healthcare Conference 2025?
Where can I watch Altimmune's (ALT) investor conference presentations?
What type of company is Altimmune (ALT)?
